PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2026

Invite Credit Card Holder to pay

Requester Details

Credit Card Holder Details

Company Details

Message to be included

Migraine is a complex neurological condition, characterized by frequent headaches that can last between four and 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances. The market is currently split into acute and preventative segments, with the majority of drugs used in treatment genericized across the 7MM (US, France, Germany, Italy, Spain, UK, Japan). The current migraine treatment landscape is mainly dominated by generic drugs, as the majority of migraine drugs have seen their patents expire. Pharmacological treatment is commonly segmented into two groups, acute (abortive) and preventative (prophylaxis) treatment.

GlobalData estimates that drug sales for migraine in 2016 were approximately $3.3 billion across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $8.7 billion at a CAGR of 10.3%. This growth will be driven by the launch of seven late-stage pipeline products. These seven drugs can be split into three classes; CGRP monoclonal antibodies, gepants and ditans, which all have a novel mechanism of action and are expected to address significant unmet needs in the migraine market.

Scope

Overview of migraine, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic, chronic), forecast from 2016 to 2026.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the migraine therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine therapy. The most promising candidates in Phase III development are profiled.

Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global migraine therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global migraine therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

Pfizer

Amgen

Eli Lilly

Teva

Alder Biopharmaceuticals

Merck & Co

Allergan

Zogenix

RedHill BioPharma

OptiNose

Supernus Pharmaceuticals

GlaxoSmithKline

SUDA

Kyorin

Eisai

Pozen

Par Pharmaceuticals

Pernix ...

Pfizer

Amgen

Eli Lilly

Teva

Alder Biopharmaceuticals

Merck & Co

Allergan

Zogenix

RedHill BioPharma

OptiNose

Supernus Pharmaceuticals

GlaxoSmithKline

SUDA

Kyorin

Eisai

Pozen

Par Pharmaceuticals

Pernix Therapeutics

Endo Pharmaceuticals

Desitin

IntelGenx

Grupe JUSTE

Grunenthal

Almirall

Aspen Japan KK

Elan Pharmaceuticals

Menarini

Vernalis

AZ

MedPointe

Impax Laboratories

Pharmacia Coporation

Mallinckrodt

Janssen

AbbVie

CoLuicd

Rinat

Labrys Biologics

Arteaus Therapeutics

Novartis

NeurAxon Pharma

Curtis AG

Promius Pharma

Achelios Therapeutics

TrioxBio

Trigmina

Biohaven Pharmaceutical

Biofrontera

Ionis Pharmaceuticals

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Migraine: Executive Summary

2.1 Migraine Market ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Migraine: Executive Summary

2.1 Migraine Market Will Grow to $8.7 Billion by 2026

2.2 Companies Often Target the Underserved Migraine Population

2.3 Current Treatments Leave Major Unmet Needs in the Migraine Market

2.4 Market Opportunities for New Entrants

2.5 Late-Stage Pipeline Drugs Will Be a Key Driver in the Migraine Market

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Migraine Classification

4.2 Etiology and Pathophysiology

4.2.1 Etiology

4.2.2 Pathophysiology

4.3 Symptoms

4.3.1 Premonitory Phase

4.3.2 Aura Phase

4.3.3 Headache Phase

4.3.4 Resolution Phase

4.4 Prognosis

4.5 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.3.1 US

5.3.2 5EU

5.3.3 Japan

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Migraine (2016–2026)

5.5.1 Total Prevalent Cases of Migraine

5.5.2 Age-Specific Total Prevalent Cases of Migraine

5.5.3 Sex-Specific Total Prevalent Cases of Migraine

5.5.4 Migraine Cases by Frequency of Occurrences

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis Overview

6.2 Treatment Overview

6.2.1 Treatment Guidelines and Leading Prescribed Drugs

6.2.2 Clinical Practice

6.2.3 Episodic Migraine

6.2.4 Chronic Migraine

6.2.5 Non-pharmacological Treatments

6.3 US

6.4 5EU

6.5 Japan

7 Competitive Assessment

7.1 Overview

7.1.1 Maxalt (rizatriptan benzoate)

7.1.2 Relpax (eletriptan hydrobromide)

7.1.3 Treximet (sumatriptan succinate + sodium naproxen)

7.1.4 Sumavel DosePro (sumatriptan succinate)

7.1.5 Rizaport (rizatriptan benzoate)

7.1.6 Onzetra Xsail (sumatriptan succinate)

7.1.7 Other Triptans

7.1.8 Botox (onabotulinum toxin A)

7.1.9 Antidepressants

7.1.10 Anti-epileptics

7.1.11 Other Therapeutic Classes

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Acute Therapies for Patients with, or at Risk of, Cardiovascular Disorders

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Lack of Acute Therapies for Patients Unresponsive to Triptan Medication

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Physician Education and Diagnosis

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Effective and Well-Tolerated Prophylactic Treatments

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Clinical Trial Mapping

9.2.1 Clinical Trials by Country and Class

9.3 Promising Drugs in Clinical Development

9.3.1 Lasmiditan (COL-144)

9.3.2 Eptinezumab (ALD-403)

9.3.3 Fremanezumab (TEV-48125)

9.3.4 Galcanezumab (LY2951742)

9.3.5 Erenumab (AMG-334)

9.3.6 Ubrogepant (MK-1602)

9.3.7 Atogepant (AGN241689)

9.3.8 SUD-001

9.4 Promising Drugs in Early-Stage Development

9.5 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 GlaxoSmithKline

10.3.1 Overview

10.3.2 Portfolio Assessment

10.3.3 SWOT Analysis

10.4 Merck & Co.

10.4.1 Overview

10.4.2 Portfolio Assessment

10.4.3 SWOT Analysis

10.5 Pfizer

10.5.1 Overview

10.5.2 Portfolio Assessment

10.5.3 SWOT Analysis

10.6 Allergan

10.6.1 Overview

10.6.2 Portfolio Assessment

10.6.3 SWOT Analysis

10.7 Amgen

10.7.1 Overview

10.7.2 Portfolio Assessment

10.7.3 SWOT Analysis

10.8 Eli Lilly

10.8.1 Overview

10.8.2 Portfolio Assessment

10.8.3 SWOT Analysis

10.9 Alder Biopharmaceuticals

10.9.1 Overview

10.9.2 Portfolio Assessment

10.9.3 SWOT Analysis

10.10 Teva

10.10.1 Overview

10.10.2 Portfolio Assessment

10.10.3 SWOT Analysis

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Migraine Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

List of tables

Table 1: Migraine: Key Metrics in the 7MM

Table 2: Migraine Classification from the ICHD-3

Table 3: Diagnostic Criteria for Migraine with Aura

Table 4 ...

Table 1: Migraine: Key Metrics in the 7MM

Table 2: Migraine Classification from the ICHD-3

Table 3: Diagnostic Criteria for Migraine with Aura

Table 4: Diagnostic Criteria for Migraine without Aura

Table 5: Risk Factors and Comorbidities for Migraine

Table 6: ICHD-3 Diagnostic Criteria for Migraine

Table 7: Total Prevalent Cases of Migraine, Ages ≥18 Years, Both Sexes, N, Select Years 2016–2026

Table 8: Treatment Guidelines for Migraine

Table 9: Most Prescribed Drugs for Migraine by Class in the 7MM, 2016

Table 10: Country Profile – US

Table 11: Country Profile – 5EU

Table 12: Country Profile – Japan

Table 13: Product Profile – Maxalt

Table 14: Maxalt SWOT Analysis, 2017

Table 15: Product Profile – Relpax

Table 16: Relpax Efficacy Clinical Trial Results

Table 17: Percentage of Patients with Headache Response (Mild or No Headache) 2 Hours Following Treatment

Table 18: Relpax SWOT Analysis, 2017

Table 19: Product Profile – Treximet

Table 20: Treximet SWOT Analysis, 2017

Table 21: Product Profile – Sumavel DosePro

Table 22: Sumavel DosePro SWOT Analysis, 2017

Table 23: Product Profile – Rizaport

Table 24: Rizaport SWOT Analysis, 2017

Table 25: Product Profile – Onzetra Xsail

Table 26: Onzetra Xsail SWOT Analysis, 2017

Table 27: Product Profile – Other Triptans

Table 28: Triptan SWOT Analysis, 2017

Table 29: Product Profile – Botox

Table 30: Botox SWOT Analysis, 2017

Table 31: Product Profiles – Antidepressants

Table 32: Antidepressants SWOT Analysis, 2017

Table 33: Product Profiles – Anti-epileptics

Table 34: Anti-epileptics SWOT Analysis, 2017

Table 35: Product Profile – Other Therapeutic Classes

Table 36: Unmet Need and Opportunity in Episodic and Chronic Migraine, 2017

Table 37: Migraine Late-Stage Pipeline, 2017

Table 38: Comparison of Therapeutic Classes in Development for Migraine, 2016–2026

Table 39: Product Profile – Lasmiditan

Table 40: Lasmiditan SWOT Analysis, 2017

Table 41: Product Profile – Eptinezumab (ALD-403)

Table 42: Eptinezumab (ALD-403) SWOT Analysis, 2017

Table 43: Product Profile – Fremanezumab (TEV-48125)

Table 44: Fremanezumab (TEV-48125) SWOT Analysis, 2017

Table 45: Product Profile – Galcanezumab (LY2951742)

Table 46: Product Profile – Erenumab (AMG-334)

Table 47: Erenumab (AMG-334) SWOT Analysis, 2017

Table 48: Product Profile – Ubrogepant (MK-1602)

Table 49: Ubrogepant (MK-1602) SWOT Analysis, 2017

Table 50: Product Profile – Atogepant (AGN241689)

Table 51: Atogepant (AGN241689) SWOT Analysis, 2017

Table 52: Product Profile – SUD-001

Table 53: SUD-001 SWOT Analysis, 2017

Table 54: Drugs in Development for Migraine, 2016

Table 55: Key Companies in the Migraine Market in the 7MM, 2016

Table 56: GlaxoSmithKline Disease Portfolio Assessment, 2017

Table 57: GSK SWOT Analysis, 2017

Table 58: Merck’s Disease Portfolio Assessment, 2017

Table 59: Merck SWOT Analysis, 2017

Table 60: Pfizer’s Disease Portfolio Assessment, 2017

Table 61: Pfizer SWOT Analysis, 2017

Table 62: Allergan’s Disease Portfolio Assessment, 2017

Table 63: Allergan SWOT Analysis, 2017

Table 64: Amgen’s Disease Portfolio Assessment, 2017

Table 65: Amgen SWOT Analysis, 2017

Table 66: Eli Lilly’s Disease Portfolio Assessment, 2017

Table 67: Eli Lilly SWOT Analysis, 2017

Table 68: Alder’s Disease Portfolio Assessment, 2017

Table 69: Alder SWOT Analysis, 2017

Table 70: Teva’s Disease Portfolio Assessment, 2017

Table 71: Teva SWOT Analysis, 2017

Table 72: Migraine Market – Global Drivers and Barriers, 2016–2026

Table 73: Key Events Impacting Sales for Migraine in the US, 2016–2026

Table 74: Migraine Market – Global Drivers and Barriers in the US, 2016–2026

Table 75: Key Events Impacting Sales for Migraine in the 5EU, 2016–2026

Table 76: Migraine Market – Global Drivers and Barriers in the 5EU, 2016–2026

Table 77: Key Events Impacting Sales for Migraine in Japan, 2016–2026

Table 78: Migraine Market – Global Drivers and Barriers in Japan, 2016–2026

Table 79: Key Historical and Projected Launch Dates for Migraine

Table 80: Key Historical and Projected Patent Expiry Dates for Migraine

Table 81: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of figures

Figure 1: Global Sales Forecast by Country for Migraine in 2016 and 2026

Figure 2: Analysis of the Company Portfolio Gap in Migraine During the ...

Figure 1: Global Sales Forecast by Country for Migraine in 2016 and 2026

Figure 2: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents Expected to be Licensed for the Treatment of Migraine During the Forecast Period

Figure 4: Pathophysiology of a Migraine

Figure 5: 7MM, Age-Standardized Total Prevalence of Migraine, Both Sexes, Ages ≥18 Years, 2016

Figure 6: Sources Used and Not Used in Epidemiological Analysis of Migraine Prevalence

Figure 7: Sources Used and Not Used in Epidemiological Analysis of Migraine Frequency

Figure 8: 7MM, Age-Specific Total Prevalent Cases of Migraine, Both Sexes, Ages ≥18 Years, 2016

Figure 9: 7MM, Sex-Specific Total Prevalent Cases of Migraine, Ages ≥18 Years, 2016

Figure 10: 7MM, Total Prevalent Migraine Cases by Frequency of Occurrences, Both Sexes, Ages ≥18 Years, 2016

Figure 11: Overview of the Development Pipeline in Migraine. Darkest circle indicates Phase III of development, the lightest circle Phase

Figure 12: Migraine Clinical Trials by Class and Country

Figure 13: Migraine Clinical Trials for Drugs in the Late-Stage Pipeline

Figure 14: A Competitive Assessment of the Late-Stage Pipeline Agents in Development for the Treatment of Migraine for 2016–2026

Figure 15: Clinical and Commercial Positioning of Lasmiditan (COL-144)

Figure 16: Clinical and Commercial Positioning of Eptinezumab (ALD-403)

Figure 17: Clinical and Commercial Positioning of Fremanezumab (TEV-48125)

Figure 18: Clinical and Commercial Positioning of Galcanezumab (LY2951742)

Figure 19: Clinical and Commercial Positioning of Erenumab (AMG-334)

Figure 20: Clinical and Commercial Positioning of Ubrogepant (MK-1602)

Figure 21: Clinical and Commercial Positioning of Atogepant (AGN241689)

Figure 22: Clinical and Commercial Positioning of SUD-001

Figure 23: Global Sales of Branded Products for Migraine by Company in 2016 and 2026

Figure 24: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period

Figure 25: Global (7MM) Sales Forecast by Country for Migraine in 2016 and 2026

Figure 26: Sales Forecast by Class for Migraine in the US in 2016 and 2026

Figure 27: Sales Forecast by Class for Migraine in the 5EU in 2016 and 2026

Figure 28: Sales Forecast by Class for Migraine in Japan in 2016 and 2026

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports